Condiciones de salud que guaraná puede ayudar a apoyar.
Guarana seed extracts exhibit strong antioxidant activity documented in vitro and in vivo in humans. An in vivo human study showed habitual guarana consumers had 27% lower LDL oxidation versus non-consumers. A small daily dose (3 g) improved oxidative stress markers in healthy subjects. Guarana's TRAP (Total Radical-Trapping Antioxidant Potential) is measurable at concentrations as low as 1 µg/mL.
Guarana seeds contain 2–8% caffeine (guaranine), theobromine, and saponins that suppress appetite and enhance thermogenesis. The combination of guarana, yerba mate, and damiana clinically slowed gastric emptying by 15–58% and induced significant weight loss over 45 days. Traditional use by Amazonian peoples as a hunger suppressant during food scarcity is well documented.
Guarana reduces LDL oxidation, a key initiating event in atherosclerosis, demonstrably in human in vivo research. Its polyphenols and caffeine exert antiatherogenic effects, and it has been traditionally listed as a preventive for arteriosclerosis in Amazon indigenous records. Epidemiological data show lower cardiovascular risk markers in habitual consumers.
Multiple placebo-controlled human trials demonstrate guarana can reduce perceived exertion and improve cognitive performance during exercise. A crossover RCT in 25 participants found guarana (125 mg/kg) decreased choice reaction time before maximal cycling versus placebo. A 2023 systematic review and meta-analysis (8 studies, 328 participants) found a small but significant effect on response time (Hedge's g = 0.202, p = 0.005). Effects on shooting performance and perceived exertion have also been documented in high-level athletes.
Guarana aqueous extract demonstrates distinct platelet aggregation inhibition both in vitro and in vivo, established in multiple publications. The active compounds are catechins, epicatechins, and their dimers in complex with caffeine. This antiplatelet activity reduces thromboxane synthesis and is potent enough to potentially interact with anticoagulant medications.
Guarana polyphenols inhibit alpha-glucosidase and alpha-amylase, reducing postprandial glucose rises. Epidemiological data from habitual guarana consumers show lower fasting glucose. Human supplementation studies have reported reductions in fasting glucose and triglycerides. Catechins and epicatechins in guarana improve insulin sensitivity by reducing oxidative damage and inflammation.
Clinical trials show guarana, particularly in combination with vitamins and minerals, can reduce mental fatigue and improve sustained attention. A double-blind RCT in 129 healthy young adults found a vitamin/mineral/guarana combination improved speed and accuracy on a rapid visual information processing task and attenuated the build-up of mental fatigue. A 2023 meta-analysis found a significant effect on response speed across cognitive tasks.
Guarana (Paullinia cupana) is a natural source of caffeine (3-5% by weight), the most-studied anti-cellulite ingredient. Caffeine from guarana inhibits phosphodiesterase and raises cAMP in adipocytes, promoting lipolysis. Guarana is used in peer-reviewed oral anti-cellulite supplement formulations and is referenced as a caffeine-delivery vehicle in the anti-cellulite context.
Guarana seed powder contains flavanols with cholesterol-lowering effects, demonstrated in vitro via inhibition of pancreatic lipase, bile acid binding, and reduced cholesterol micellar solubilization. A human epidemiological study found female guarana consumers had lower total and LDL cholesterol. In vitro studies show guarana inhibits LDL oxidation by 27% in regular consumers versus non-consumers.
Multiple clinical trials support guarana's ability to reduce fatigue, including cancer-related fatigue. A pivotal double-blind RCT in breast cancer chemotherapy patients (n=75) found guarana extract significantly improved fatigue scores (FACIT-F, BFI) versus placebo at days 21 and 49. A systematic review and meta-analysis of 7 studies (427 cancer patients) supports guarana for cancer-related fatigue management. Traditional use by Amazonian peoples for fatigue predates these findings.
Guarana seed extracts and bioactive compounds (catechins, theobromine, caffeine) have demonstrated anti-inflammatory activity in multiple in vitro and animal models. In a rat hyperlipidemia model, guarana shifted cytokine profiles from pro- to anti-inflammatory, outperforming caffeine alone. In silico molecular docking confirms strong binding of guarana catechins to PDE4B, a key inflammatory enzyme.
Habitual guarana consumption in an elderly Amazonian population was associated with lower oxidative stress markers and lower prevalence of metabolic conditions that drive cognitive decline. In vitro studies demonstrate neuroprotective and antiaging properties. Guarana improved memory in a rat model of hyperlipidemia-associated cognitive impairment. A 2021 systematic review supports guarana for cancer-related fatigue in aging patients.
A pilot double-blind randomized crossover RCT (36 breast cancer patients) assessed guarana for post-radiation depression and fatigue. Animal models show chronic guarana seed extract exposure produces anxiolytic effects involving dopaminergic and serotonergic neurotransmission. Traditional Amazonian medicine lists guarana among remedies for low mood and depression.
Guarana (Paullinia cupana) seeds contain approximately 2–4.5% caffeine, along with theobromine and theophylline, giving it stimulant and energy-boosting properties. Indigenous Amazonian peoples have long used guarana as a stimulant and energy food. A PMC meta-analysis found guarana significantly alleviated cancer-related fatigue in clinical trials.
Guarana (Paullinia cupana) seeds contain high concentrations of caffeine plus theobromine, theophylline, and tannins. Multiple RCTs demonstrate improvements in attention, memory, and psychomotor speed with guarana extracts, including evidence of superior effects versus matched doses of pure caffeine alone. It has been used traditionally by Amazonian peoples for mental energy and endurance.
Guarana (Paullinia cupana) seeds contain high concentrations of caffeine (3–5% by weight, higher than coffee) along with theobromine and theophylline, providing robust thermogenic, lipolytic, and appetite-suppressing effects. A clinical study in healthy adults found guarana-containing supplements increased energy expenditure and reduced body weight as part of combination weight management regimens.
Guarana has demonstrated multiple cardioprotective properties in human and in vitro research: inhibition of platelet aggregation (in vitro and in vivo), reduction of LDL oxidation in elderly human consumers, anti-inflammatory activity in lipotoxic models, and epidemiological association with lower cardiovascular risk biomarkers. Theobromine also uniquely influences cardiovascular function through vasodilation.
Guarana polyphenols, including catechin and epicatechin, support insulin sensitivity by inhibiting alpha-glucosidase, reducing LDL oxidation, and modulating inflammation and oxidative stress. Human epidemiological data show lower rates of hyperinsulinemia and metabolic syndrome in habitual guarana consumers. Preclinical models show prevention of insulin resistance in dietary obesity models.
Human and animal evidence suggests guarana can modulate memory-related processes. In a rat model of hyperlipidemia-induced cognitive impairment, guarana improved memory and reduced acetylcholinesterase activity in brain tissue. In human trials, secondary memory improvements have been observed in placebo-controlled settings. The mechanism involves methylxanthine-mediated adenosine blockade facilitating norepinephrine-dependent memory consolidation.
Guarana (Paullinia cupana) seeds contain high concentrations of caffeine along with theophylline and theobromine. Multiple clinical studies confirm it improves mental alertness, reaction time, memory, and attention. It has traditional use among Amazonian indigenous peoples as a stimulant and fatigue-fighter.
The landmark Krewer et al. (2011, Phytotherapy Research) epidemiological study of an elderly Amazonian population found the prevalence of metabolic syndrome was significantly lower in habitual guarana consumers compared to non-consumers. This was accompanied by lower rates of obesity, hypertension, and improved lipid and oxidative biomarkers. Animal models support guarana's anti-obesity and lipid-correcting effects.
Guarana's caffeine content increases metabolic rate via thermogenesis and AMPK activation, effects well established for methylxanthines. Epidemiological data link habitual guarana consumption to lower obesity prevalence and better metabolic biomarkers in elderly Amazonian people. Animal studies confirm anti-adipogenic and metabolic-correcting effects across obesity models.
Guarana is a well-documented CNS stimulant via caffeine-mediated adenosine receptor antagonism. Animal studies show neuroprotective properties and anxiolytic effects involving serotonergic and dopaminergic systems. Guarana has also been shown in preclinical models to reduce neuronal oxidative stress and protect against hyperlipidemia-induced cognitive impairment.
Guarana's primary mechanism of action involves adenosine receptor antagonism by caffeine, which modulates the release of norepinephrine, dopamine, acetylcholine, glutamate, and serotonin. Chronic exposure to guarana seed extract has been shown in animal models to produce anxiolytic effects via dopaminergic and serotonergic neurotransmission. These effects underpin its cognitive and mood-related properties.
Guarana (Paullinia cupana) is a natural caffeine-containing plant from the Amazon traditionally used by indigenous peoples for stamina and endurance. It contains 2–4.5% caffeine along with theobromine and theophylline, providing a more sustained stimulant effect than coffee. Multiple studies confirm its ergogenic effects are primarily attributable to caffeine content, improving endurance, reducing fatigue, and enhancing physical performance.
Guarana (Paullinia cupana) seeds contain high concentrations of caffeine (2–8%) along with theophylline and theobromine, making it a traditional and scientifically supported thermogenic. Multiple clinical studies and reviews confirm its thermogenic activity, largely attributed to its methylxanthine content. It is a common thermogenic ingredient in energy and fat-burning supplements.
Human and animal data indicate guarana reduces serum triglycerides. A human supplementation study in overweight subjects showed guarana significantly lowered triglycerides and oxidative biomarkers independent of weight loss. Animal studies confirm reductions in triglycerides in hyperlipidemic and obese models. The 2011 elderly population epidemiological study associated guarana consumption with better lipid profiles.
Guarana has been traditionally used for arthritis and rheumatism by Amazonian indigenous peoples and in Peruvian folk medicine. The use is supported by documented ethnobotanical records, with plausible anti-inflammatory mechanisms from its polyphenol and methylxanthine content, though no clinical trials in arthritic populations have been published.
Guarana's use against diarrhea is among its oldest documented traditional applications, stemming from its high tannin content, which exhibits astringent properties capable of reducing intestinal secretion. Indigenous groups across the Amazon basin and in Peru have used guarana for chronic diarrhea and dysentery. No dedicated human clinical trials have been conducted.
Guarana has longstanding documented traditional use by Amazonian indigenous peoples for treating headaches. The first written record from a 1669 Jesuit expedition documents the Sateré-Mawé people using guarana against headaches. The caffeine content offers a plausible mechanism, as caffeine is a recognized headache remedy, but no dedicated clinical trials on guarana specifically for headaches have been published.
Guarana's use for migraine is documented in Peruvian and broader Amazonian traditional medicine, with caffeine's vasoconstrictive properties providing a pharmacological rationale. It appears in multiple ethnobotanical records alongside headache treatment. No clinical trials specifically targeting migraine with guarana have been published.
Volver